Nasdaq:ONC
BeOne Medicines Ltd.
A clinical-stage biotech firm with massive cash hoards, recent profitability, and a robust revenue growth trajectory from $1.42B in 2022 to $5.34B in 2025.
Key Metrics
Investment Thesis
Bull Case
ONC presents a compelling value play for investors seeking exposure to biotech turnaround stories with a fortress balance sheet. The transition to profitability in 2025 combined with a 275% revenue growth over three years suggests the company has successfully de-risked its pipeline and achieved commercial traction.",
Bear Case
Despite recent profits, the massive retained earnings deficit of -$8.32B indicates a history of heavy cash burning that requires careful monitoring. Investors should be wary of the high operating expenses relative to revenue and the reliance on non-operating financing cash flows which could signal future equity dilution if operational cash generation falters.",
About BeOne Medicines Ltd.
BeOne Medicines Ltd. (ONC) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics primarily in oncology and immunology markets. The company leverages its extensive R&D pipeline to pursue differentiated treatments while managing significant cash reserves of $4.55B to fund operations.
Analysis
Management Discussion
The company demonstrated a remarkable turnaround in 2025, shifting from multi-billion dollar losses to generating $286.9M in net profit while scaling revenue to $5.34B. Operating expenses rose to $4.23B, but this was offset by massive cash inflows and a strong operating profit of $447.1M.",
Industry Overview
The biopharmaceutical industry is currently characterized by intense competition for oncology approvals and a heavy reliance on R&D investment, with successful transitions from clinical stages to commercialization being rare. Companies like ONC that can achieve profitability early while maintaining a strong cash position are increasingly valued in this sector.",
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.42B | $2.46B | $3.81B | $5.34B |
| Cost of Revenue | $286.5M | $379.9M | $594.1M | $668.5M |
| Gross Profit | $1.13B | $2.08B | $3.22B | $4.67B |
| Operating Expenses | $2.92B | $3.29B | $3.78B | $4.23B |
| Operating Income | $-1.79B | $-1.21B | $-568.2M | $447.1M |
| R&D | $1.64B | $1.78B | $1.95B | $2.15B |
| G&A | $1.28B | $1.50B | $1.83B | $2.08B |
| Stock-Based Comp | $303.2M | $367.6M | $441.6M | $510.9M |
| D&A | $66.3M | $87.7M | $171.8M | $141.7M |
| Depreciation | $62.3M | $80.4M | $166.9M | $131.6M |
| Amortization | $4.0M | $7.2M | $4.8M | $10.1M |
| Other OpEx | $751.0K | $3.5M | $0 | $0 |
| Non-Operating Income | $-171.4M | $381.9M | $35.2M | $-30.3M |
| Interest Income | — | — | — | $70.5M |
| Pre-Tax Income | $-1.96B | $-825.8M | $-533.0M | $416.9M |
| Income Tax | $42.8M | $55.9M | $111.8M | $129.9M |
| Continuing Ops | $-2.00B | $-881.7M | $-644.8M | $286.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-2.00B | $-881.7M | $-644.8M | $286.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-2.00B | $-881.7M | $-644.8M | $286.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $5.21B | $4.20B | $3.99B | $6.23B |
| Cash & Equivalents | $3.87B | $3.17B | $2.63B | $4.55B |
| Marketable Securities | $665.3M | $2.6M | — | — |
| Accounts Receivable | $173.2M | $358.0M | $676.3M | $865.1M |
| Inventory | $282.3M | $416.1M | $495.0M | $608.2M |
| Prepaid Expenses | $216.6M | $243.4M | $192.9M | $212.8M |
| Other Current Assets | $196.0K | $11.5M | $0 | $0 |
| Long-Term Assets | $1.17B | $1.60B | $1.93B | $1.95B |
| PP&E (Net) | $845.9M | $1.32B | $1.58B | $1.64B |
| Goodwill | $109.0K | — | — | — |
| Operating Leases | $110.0M | $95.2M | $139.3M | $148.2M |
| LT Investments | $91.8M | $89.6M | $128.9M | $61.7M |
| Other LT Assets | $124.4M | $92.9M | $49.6M | $81.1M |
| Total Assets | $6.38B | $5.81B | $5.92B | $8.19B |
| Current Liabilities | $1.47B | $1.81B | $2.21B | $1.83B |
| Accounts Payable | $294.8M | $315.1M | $405.0M | $479.0M |
| Current Debt | $329.0M | $688.4M | $851.5M | $57.3M |
| Current Leases | $24.0M | $21.9M | $17.6M | $20.7M |
| Deferred Revenue | $213.9M | $0 | — | — |
| Taxes Payable | $18.8M | $30.1M | — | — |
| Other Current Liab | $120.7M | $60.9M | $137.1M | $162.7M |
| Long-Term Liabilities | $527.4M | $457.8M | $373.8M | $2.00B |
| Long-Term Debt | $209.1M | $197.6M | $166.5M | $961.9M |
| LT Operating Leases | $34.5M | $22.3M | $44.3M | $52.9M |
| Other LT Liab | $241.7M | $237.7M | $163.0M | $983.7M |
| Total Liabilities | $2.00B | $2.27B | $2.59B | $3.83B |
| Shareholders' Equity | $4.38B | $3.54B | $3.33B | $4.36B |
| Paid-In Capital | $11.54B | $11.60B | $12.09B | $12.76B |
| Retained Earnings | $-7.08B | $-7.96B | $-8.61B | $-8.32B |
| AOCI | $-77.4M | $-99.4M | $-149.0M | $-78.2M |
| Total L&E | $6.38B | $5.81B | $5.92B | $8.19B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-2.00B | $-881.7M | $-644.8M | $286.9M |
| Non-Cash Adjustments | $863.1M | $-539.5M | $-90.3M | $207.8M |
| Working Capital Changes | $-355.9M | $263.7M | $594.5M | $632.8M |
| Cash from Operations | $-1.50B | $-1.16B | $-140.6M | $1.13B |
| Capital Expenditures | $325.4M | $561.9M | $492.7M | $185.8M |
| Cash from Investing | $1.08B | $60.0M | $-548.4M | $-276.2M |
| Debt Repayments | $0 | $13.7M | $28.0M | $35.7M |
| Cash from Financing | $-19.0M | $416.5M | $193.4M | $1.06B |
| FX Effect | $-69.4M | $-8.1M | $-51.7M | $60.0M |
| Net Change in Cash | $-507.9M | $-689.1M | $-547.2M | $1.97B |
| Beginning Cash | $4.38B | $3.88B | $3.19B | $2.64B |
| Ending Cash | $3.88B | $3.19B | $2.64B | $4.61B |
Frequently Asked Questions
How does BeOne Medicines Ltd. make money?
Oncology therapeutics development, immunology research programs, and pre-commercialization R&D activities supported by substantial government or grant funding reflected in the cash flow structure.
What are the main risks for ONC?
High dependence on external funding sources given the historically large retained earnings deficit of -$8.32B, potential regulatory hurdles for novel oncology drugs, and volatility in cash flow from financing activities which dropped to $1.06B recently.",
What is ONC's competitive advantage?
Significant liquidity buffer with $4.61B in cash allowing for extended runway without dilution, a highly efficient recent conversion to profitability with $286.9M net income, and a scalable R&D model evidenced by $2.15B invested in research.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.